Member Info for EmeraldCarrots

Catch the circulating tumour cells (CTC's). With Parsortix the CTC's are 99% ALIVE, intact and uncontaminated by the very process used to catch them. Then they are analysed to help "program" the "T" killer cells also found in the blood. The cells are the infused back into the patient.

Looking extremely promising indeed.

https://investors.immatics.com/news-releases/news-release-details/immatics-highlights-compelling-anti-tumor-activity-anzu-cel-0

https://immatics.com/our-pipeline/

All IMHO.

Https://investors.immatics.com/news-releases/news-release-details/immatics-highlights-compelling-anti-tumor-activity-anzu-cel-0

cORR of 67%:- In a cancer context, a confirmed objective response rate (cORR) of 67% means that

67% of the patients treated with a specific therapy had their cancer measurably shrink or disappear completely.

--------------------

mDOR of 11.0 months. Means the median duration of response to a particular treatment is 11 months.

Median (m): The median is the midpoint of a data set. In this case, it means that for a group of patients who responded positively to a cancer treatment, half of them continued to respond for at least 11 months, and the other half responded for less than 11 months.

Duration of Response (DoR): The DoR is the length of time a tumor continues to shrink or not grow (respond) in reaction to a treatment, without the disease progressing.

11.0 months: This is the specific time frame of the median response

-------------------

mPFS of 8.5 months:-

For cancer, a median progression-free survival (mPFS) of 8.5 months means that, in a clinical study, half of the patients lived at least 8.5 months without their cancer growing or spreading. This indicates how effective a treatment is at controlling a disease, not necessarily curing it.

-------------------

and mOS not reached at 14.3 months mFU:-

For cancer, a median progression-free survival (mPFS) of 8.5 months means that, in a clinical study,

half of the patients lived at least 8.5 months without their cancer growing or spreading. This indicates how effective a treatment is at controlling a disease, not necessarily curing it. More than half of the patients in the study were still alive after a median follow-up time of 14.3 months. This is a very positive outcome, indicating that the new treatment is highly effective.

https://immatics.com/our-pipeline/

Maybe the market cap of £8m has caught someon's attention, since it was North of £150m a while back!

Maybe the markey cap of £8m has caught someon's attention, since it was North of £150m a while back!

So still 47.6% up over the two days. Surprising and interesting. Food for some thought. Is this more than just the Immatics news? Is there progress with the NHS dual analysis trial? Is there news from Illumina to come? Have Astrazeneca decided to use Angle Plc to help in a drugs trial?

One wonders if this will go from phase 1a to 2b. Interesting stuff. I Like the Moderna connection.

https://www.pbs.org/newshour/health/mrna-covid-vaccines-may-be-helping-some-cancer-patients-fight-tumors-researchers-say

https://immatics.com/our-pipeline/

Correction.

Trial. So If Immatics phase 3 Anzu-cel (IMA 203) 2L melanoma drug trial Is a success then the recently departed CEO, Andrew Newland will suddenly be very popular as opposed to the current IMHO sentiment! From disaster to a roaring success. I certainly hope it is success!!! The sp here really moves so back to 15p or more on success IMHO.

https://immatics.com/our-pipeline/

AI Overview

Parsortix is used in Immatics' IMA203 trial to select patients for the study, specifically those with PRAME-expressing tumors (the target for the T-cell therapy), and to monitor treatment response. The Parsortix system isolates circulating tumor cells (CTCs) from blood samples, allowing researchers to confirm tumor presence and analyze the cells' characteristics to identify patients who have the target antigen and are likely to benefit from the therapy.

How Parsortix is used in the IMA203 trial

Patient selection: The IMA203 therapy is a T-cell receptor (TCR-T) therapy, meaning it relies on engineered T-cells that specifically recognize and bind to a target on cancer cells, in this case, PRAME.

Parsortix isolates CTCs from a patient's blood.

These captured CTCs are then analyzed to confirm if they express the PRAME target antigen.

This confirmation is crucial for selecting patients who are most likely to respond to the IMA203 therapy.

Monitoring treatment response: After a patient receives the therapy, the Parsortix system can be used again to monitor how the treatment is working.

The system can analyze the number and characteristics of CTCs over time to assess if the treatment is effectively reducing the number of cancer cells in the blood.

This ongoing monitoring helps to track the progression of the disease and the effectiveness of the T-cell therapy.

======

https://immatics.com/our-pipeline/

https://investors.immatics.com/news-releases/news-release-details/immatics-highlights-compelling-anti-tumor-activity-anzu-cel-0

=====

Trial that made it past phase 3 we would all be rich. Very, very rich. I believe Immatics catch live, intact, uncontaminated circulating tumour cells (CTC's) from the drug trial participants. Then the CTC's are analysed to find out how they can be targeted by the "T" cells that are probably caught at the same time. This is personalised cancer treatment as everyone's cancer is slightly different (and indeed changes over time). So, if it ends up in use at hospitals every person that needs the treatment will need to have their CTC's analysed. Thousands of people one would have thought per month.

We will see!

All IMHO.

A.I.

Kicking off 5 searches

Looking at 77 sites

Putting it all together

ANGLE plc shares went up on Tuesday, October 21, 2025, primarily due to positive investor sentiment driven by external news rather than any specific company announcement

. The biotech sector as a whole was buoyed by positive news regarding a cancer drug trial from another company, Immatics, which led to speculation about ANGLE's related technology.

Key market movements on Tuesday, October 21, 2025

Immatics trial news: A cancer drug trial that uses ANGLE's Parsortix technology showed good results, advancing from phase 1b to phase 2. Another trial using the same drug was already in phase 3, with results expected in the same quarter, further boosting confidence in the technology.

Wider market sentiment: Positive news around the Immatics trial spurred broader optimism regarding ANGLE's Parsortix system, which captures circulating tumor cells (CTCs) for analysis. Investors speculated that this development could drive further use of ANGLE's technology by pharmaceutical companies.

Biomarkers in glioblastoma. Parsortix used.

https://www.labroots.com/webinar/novel-strategies-circulating-tumor-cell-analysis-glioblastoma?srsltid=AfmBOoqkBljI05TwZCD7U4-gICmyNGzEOgY8m36hhBpVdUhUbC5SFHVv

Sorry.

There are increasing amouts of buys it seems. Wonder what the USA players will do when they wake up? Now down to minius 16% form minus 18%. What is going on here?

Today. Certainly volitile, and thus far today is nit good! LOL!

Something afoot.

Or do you just comment on other peoples informative posts and contribute sweet FA?

As that NASDAQ quoted company is collaborating with Angle to evaluate possibly adding dual analysis to their already established solid tissue DNA analysis

Https://www.biorxiv.org/content/10.1101/2025.10.13.681971v1.full

At what you have posted on this site. What on earth is the point? Are you a troll?

??

Up 6.78%.